10月1日，加拿大航天局（CSA）宇航员约书亚·库特里克（Joshua Kutyrk）将从佛罗里达州卡纳维拉尔角发射升空，他此行将携带一些创新的加拿大技术。
On Oct. 1 Canadian Space Agency (CSA) astronaut Joshua Kutyrk will blast off from Cape Canaveral, Fla., and he’s bringing some innovative Canadian tech with him.
在太空中生活和工作是一项危险的工作。我们的身体并非为低重力环境而生，宇航员可能会经历一系列不同的副作用。
Living and working in space is a dangerous job. Our bodies weren’t made for living in low gravity, and astronauts can experience a slew of different side effects.
这包括形成极其危险的血栓的可能性。这种情况确实发生过，尽管出于隐私考虑，我们不知道具体是谁。美国国家航空航天局（NASA）非常关注确保在轨道实验室生活的宇航员的安全。
That includes the potential to develop extremely dangerous blood clots, which has happened, though we don’t know to whom due to privacy concerns. And NASA is very interested in ensuring the safety of astronauts living on the orbiting laboratory.
加拿大航天局宇航员办公室主任马修·卡隆（Mathieu Caron）表示：“多年来，我们花费了大量时间研究人类在太空中停留数周或数月时身体会发生什么变化。其中一些医学问题与血栓的形成有关。”
“Over the years, we have spent a lot of time investigating what happens to the human body when humans go to space for weeks, months at a time. And there have been some medical concerns associated with formation of blood clots,” said Mathieu Caron, director of CSA’s astronaut office.
“这促使NASA寻找不同的方法来准确量化风险，以了解我们是否接近出现问题的临界点。”这就是他们委托温哥华Response Biomedical公司开发相关技术的原因。
“That prompted NASA to look at different ways to properly quantify the risk, to understand, you know, are we close to a problem or not?” That’s why they’ve commissioned technology from Vancouver-based Response Biomedical.
NASA特别感兴趣的一种仪器是能够测量血液中D-二聚体含量的设备，这是一种血栓溶解后残留在血液中的蛋白质片段。
One instrument of particular interest to NASA was one that measures the D-dimer in blood, a protein fragment left over in the blood after a clot.
他表示，这是地面飞行外科医生最关键的信息来源之一。他说，NASA选择与加拿大航天局合作，是因为后者在空间站的健康和生命科学研究方面拥有丰富经验。
He said this is one of the most crucial pieces of information for flight surgeons on the ground. NASA chose CSA because of its experience with health and life science research on the space station, he said.
该设备被称为“太空急性护理检测”（ACTIS），源自该公司现有的RAMP技术。这些设备不仅可以检测血栓，还可以寻找心脏病发作的迹象，或用于检测新冠病毒、呼吸道合胞病毒（RSV）等。
Called Acute Care Testing in Space (ACTIS), the device is taken from the company’s existing RAMP technology. These devices can not only look for blood clots but also look for evidence of heart attacks or testing for COVID-19, RSV and more.
Response Biomedical首席执行官塔索·索尼斯（Taso Tsonis）表示，这种简单的血液检测可以在几分钟内完成，使其比其他检测方法高效得多。用于偏远社区“这是一个关于我们加拿大开发的平台如今如何在国际空间站上得到国际应用的出色案例，但我们持续关注的重点仍然是在地球上，”Tsonis说道。
The simple blood test can be done within minutes, making it far more efficient than others, said Taso Tsonis, CEO of Reponse Biomedical. Used in remote communities“It's a great story of how our Canadian-developed platform is being used internationally now on the International Space Station, but our continued focus is here on Earth,” Tsonis said.
“并将检测推进到更可靠、便携且能在患者身边完成的水平，大约15分钟就能得到结果，而不必为了一份关键的检测结果等待数小时。”这种及时性对于生活在地球上偏远社区的人们来说同样重要，因为在那些地方，检测条件可能有限，时间也至关重要。
“And advancing testing to more reliable testing that's portable and near a patient where you can get a result in about 15 minutes as opposed to waiting for hours for a critical test result.” That timeliness is also important to those living in remote communities here on Earth, where testing may be limited and time may be of the essence.
“很多时候，医疗系统不仅因不必要的治疗和不必要的入院而负担沉重，还因为人们无法得到足够快速的评估，”Tsonis说。
"A lot of times, health-care systems are burdened by either unnecessary treatment, unnecessary admissions, but also people who are not assessed quickly enough," Tsonis said.
周日致敬：您对阿尔伯塔省宇航员Joshua Kutryk的提问。加拿大宇航员Joshua Kutryk将于下周前往国际空间站。Tsonis表示，他很兴奋地想到，如果Kutryk对该技术的测试进展顺利，ACTIS或许能走得比国际空间站更远——随着美国国家航空航天局（NASA）计划进行更多人类太空探索，它甚至可能前往月球或火星。
Sunday Shoutout, your questions for Alberta astronaut Joshua Kutryk Canadian astronaut Joshua Kutryk is heading to the ISS next week Tsonis said that he's excited to think that, should Kutryk's testing of the technology go well, ACTIS could perhaps travel farther than the ISS — perhaps to the moon or even Mars, as NASA plans for more human space exploration.
Caron和Tsonis都表示，ACTIS被选中用于国际空间站是加拿大的一次胜利。
And both Caron and Tsonis said the fact that ACTIS was chosen for the ISS is a win for Canada.
“对我们来说，这证明了我们技术的灵活性和持久价值，证明我们参与了一段创新之旅，尤其是在当今的环境下，”Tsonis说。“作为一家完全在加拿大运营的加拿大公司，这意义重大。”
“For us, it demonstrates the flexibility and the enduring value of our technology that we are part of an innovative journey, and especially in today's climate,” Tsonis said. “Being a Canadian company operating solely in Canada.”